Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**CLINUVEL PHARMACEUTICALS LTD**
ABN	**88 089 644 119**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	6 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest (Unlisted Performance Rights)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	26 August 2020
No. of securities held prior to change	3,504,696 Ordinary Shares (includes 3,399,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) NIL Unlisted Performance Rights
Class	Unlisted Performance Rights
Number acquired	1,513,750
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$Nil

For personal use only

No. of securities held after change	3,504,696 Ordinary Shares (includes 3,399,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Performance Rights ('Rights') after acceptance of offer by the Board to grant Rights and as approved by shareholders at the Company's 2019 Annual General Meeting and under the terms to the Company's 2014 Performance Rights Plan.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change **Note: Details are only required for a contract in relation to which the interest has changed**	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

For personal use only